CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma

Background Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In the evaluation of AI, it is generally recommended that PCC be excluded by measurement of plasma-free or 24-hour urinary fractionated metanephrines. However, recent studies suggest that biochemical exclusion of PCC not be performed for lesions with CT characteristics of an adrenocortical adenoma (ACA). Aim To determine the proportion of PCCs with ACA-like attenuation or contrast washout on CT. Methods For this multicenter retrospective study, two central investigators independently analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor size, unenhanced Hounsfield units (HU), absolute percentage washout (APW), and relative percentage washout (RPW) were collected in addition to clinical parameters. Results Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an attenuation of >10 HU (99.5%). In the two exceptions (0.5%), unenhanced attenuation was exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA. Of 76 PCCs with unenhanced HU > 10 and available washout data, 22 (28.9%) had a high APW and/or RPW, suggestive of ACA. Conclusion Based on the lack of PCCs with an unenhanced attenuation of <10 HU and the low proportion (0.5%) of PCCs with an attenuation of 10 HU, it seems reasonable to abstain from biochemical testing for PCC in AIs with an unenhanced attenuation of ≤10 HU. The assessment of contrast washout, however, is unreliable for ruling out PCC.

[1]  J. Stoker,et al.  Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. , 2018, European journal of endocrinology.

[2]  T. Links,et al.  Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. , 2018, European journal of internal medicine.

[3]  Seung Hyup Kim,et al.  Pheochromocytoma as a frequent false-positive in adrenal washout CT: A systematic review and meta-analysis , 2018, European Radiology.

[4]  W. Young,et al.  Pheochromocytoma with Synchronous Ipsilateral Adrenal Cortical Adenoma , 2017, World Journal of Surgery.

[5]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[6]  C. Schalin-Jäntti,et al.  A 5-Year Prospective Follow-Up Study of Lipid-Rich Adrenal Incidentalomas: No Tumor Growth or Development of Hormonal Hypersecretion , 2015, Endocrinology and metabolism.

[7]  Jee Soo Kim,et al.  Is Preoperative Biochemical Testing for Pheochromocytoma Necessary for All Adrenal Incidentalomas? , 2015, Medicine.

[8]  A. Gimenez-Roqueplo,et al.  Paraganglioma and phaeochromocytoma: from genetics to personalized medicine , 2015, Nature Reviews Endocrinology.

[9]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[10]  D. Tso,et al.  Scanner and kVp dependence of measured CT numbers in the ACR CT phantom , 2013, Journal of applied clinical medical physics.

[11]  A. Vicha,et al.  Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options , 2013, Current opinion in endocrinology, diabetes, and obesity.

[12]  C. Schalin-Jäntti,et al.  Is biochemical screening for pheochromocytoma in adrenal incidentalomas expressing low unenhanced attenuation on computed tomography necessary? , 2012, The Journal of clinical endocrinology and metabolism.

[13]  S. Siegelman,et al.  Medical and surgical evaluation and treatment of adrenal incidentalomas. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  S. Bornstein,et al.  Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. , 2010, Endocrine-related cancer.

[15]  F. Beuschlein,et al.  Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. , 2009, European journal of endocrinology.

[16]  G. Reimondo,et al.  Management of adrenal incidentaloma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[17]  W. Young The incidentally discovered adrenal mass , 2007 .

[18]  M. Pujana,et al.  Novel pheochromocytoma susceptibility loci identified by integrative genomics. , 2005, Cancer research.

[19]  Giles W Boland,et al.  Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. , 2003, AJR. American journal of roentgenology.

[20]  G. Palù,et al.  Prevalence and natural history of adrenal incidentalomas. , 2003, European journal of endocrinology.

[21]  Jennifer Reed,et al.  Evaluation and Management of the Incidental Adrenal Mass , 2003, Proceedings.

[22]  B. Ahrén,et al.  Adrenal incidentaloma – experience of a standardized diagnostic programme in the Swedish prospective study , 2002, Journal of internal medicine.

[23]  W. Arlt,et al.  Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis , 2016 .

[24]  W. Young Clinical practice. The incidentally discovered adrenal mass. , 2007, The New England journal of medicine.

[25]  PHÆOCHROMOCYTOMA , 1954, Journal of the Indian Medical Association.